 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | 177Lu-DTPA-omburtamab - Y / mAbs Therap
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma (clinicaltrials.gov) - Aug 18, 2022
P1/2, N=2, Terminated, Sponsor: Y-mAbs Therapeutics
N=40 --> 2 | Trial completion date: Dec 2024 --> Aug 2022 | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Aug 2022; Business priorities
- | 177Lu-DTPA-omburtamab - Y / mAbs Therap
Enrollment change, Trial withdrawal: 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) (clinicaltrials.gov) - Jul 15, 2022
P1/2, N=0, Withdrawn, Sponsor: Y-mAbs Therapeutics
N=40 --> 2 | Trial completion date: Dec 2024 --> Aug 2022 | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Aug 2022; Business priorities N=63 --> 0 | Not yet recruiting --> Withdrawn
- |||| 177Lu-DTPA-omburtamab - Y / mAbs Therap
Clinical, FDA event: FDA Grants Rare Pediatric Disease Designation to 177Lu-Omburtamab-DTPA for Medulloblastoma https://t.co/lr2g12w3fx via @onclive (Twitter) - Oct 15, 2021
- 177Lu-DTPA-omburtamab - Y / mAbs Therap
A phase I/II trial of intracerebroventricular 177Lu DTPA omburtamab radioimmunotherapy for leptomeningeal metastasis from solid tumors (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_400;
P1/2
The study has been approved by each institution’s ethics board, and patients provided informed consent before taking part. Trial Registration NCT04315246
- ||| 177Lu-DTPA-omburtamab - Y / mAbs Therap
Enrollment open: 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) (clinicaltrials.gov) - Sep 1, 2021
P1/2, N=63, Recruiting, Sponsor: Y-mAbs Therapeutics
Trial Registration NCT04315246 Not yet recruiting --> Recruiting
- || 177Lu-DTPA-omburtamab - Y / mAbs Therap
Enrollment open: 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma (clinicaltrials.gov) - Sep 1, 2021
P1/2, N=40, Recruiting, Sponsor: Y-mAbs Therapeutics
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- omburtamab I-131 (131 I-8H9) - Y / mAbs Therap
[VIRTUAL] A phase I/II dose-escalation and expansion cohort study of intracerebroventricular radioimmunotherapy using 177Lu-DTPA-omburtamab in pediatric and adolescent patients with recurrent or refractory medulloblastoma () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1753;
P1/2
Up to 25 pts are expected to participate in Part 1 and 24 in Part 2. Key inclusion criteria include age 3-19 years; histologically confirmed medulloblastoma; available molecular classification; recurrent/refractory to frontline therapy; Lansky or Karnofsky score of 50-100, acceptable hematological status and liver and kidney function, and a life expectancy of >3 months.
- | 177Lu-DTPA-omburtamab - Y / mAbs Therap
Trial completion date, Trial primary completion date: 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma (clinicaltrials.gov) - Apr 16, 2020
P1/2, N=40, Not yet recruiting, Sponsor: Y-mAbs Therapeutics
Key inclusion criteria include age 3-19 years; histologically confirmed medulloblastoma; available molecular classification; recurrent/refractory to frontline therapy; Lansky or Karnofsky score of 50-100, acceptable hematological status and liver and kidney function, and a life expectancy of >3 months. Trial completion date: May 2024 --> Oct 2024 | Trial primary completion date: May 2024 --> Oct 2024
- |||| 177Lu-DTPA-omburtamab - Y / mAbs Therap
New P1/2 trial: 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) (clinicaltrials.gov) - Mar 18, 2020
P1/2, N=63, Not yet recruiting, Sponsor: Y-mAbs Therapeutics
- || 177Lu-DTPA-omburtamab - Y / mAbs Therap
New P1/2 trial: 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma (clinicaltrials.gov) - Nov 18, 2019
P1/2, N=40, Not yet recruiting, Sponsor: Y-mAbs Therapeutics